[Systematic action-Emergencies in systemic cancer therapy!]

Area of Science:

• Oncology
• Urology
• Pharmacology

Background:

• Diverse systemic therapies for urologic cancers have emerged, including chemotherapy, targeted therapies, and radioligand therapies.
• Urologists frequently encounter adverse events from these treatments, necessitating updated knowledge.
• The continuous development of new drugs and drug classes requires ongoing education for managing associated toxicities.

Purpose of the Study:

• To provide a comprehensive overview of common emergency situations in genitourinary cancers.
• To outline the essential management strategies for these emergencies.

Main Methods:

• A summary of frequently observed emergency situations linked to systemic therapy in uro-oncology.
• Review of critical adverse events and their clinical implications.

Main Results:

• Urologists need expertise in managing neutropenic fever during chemotherapy and hand-foot syndrome with tyrosine kinase inhibitors.
• Knowledge of immune-related adverse events and side effects from radioligand therapies is essential.
• Effective management requires understanding emergencies regardless of who administers the therapy.

Conclusions:

• Fundamental knowledge of side effects and emergencies associated with genitourinary cancer treatments is imperative.
• Continuous medical education is mandatory to address advancements in systemic uro-oncology therapies.
• Urologists must be prepared to manage a wide spectrum of adverse events and emergencies.